Φορτώνει......
Epigenetic preconditioning with decitabine sensitizes glioblastoma to temozolomide via induction of MLH1
INTRODUCTION: To improve the standard treatment paradigm for glioblastoma (GBM), efforts have been made to explore the efficacy of epigenetic agents as chemosensitizers. Recent data suggest possible synergy between decitabine (DAC), a DNA hypomethylating agent, and temozolomide (TMZ) in GBM, but the...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | J Neurooncol |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Springer US
2020
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7256087/ https://ncbi.nlm.nih.gov/pubmed/32193690 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-020-03461-4 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|